Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aclaris Therapeutics Inc

ACRS
Current price
0.99 USD -0.014 USD (-1.36%)
Last closed 0.98 USD
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 64 007 588 USD
Yield for 12 month -93.80 %
Week
Month
Year
ACRS
21.11.2021 - 28.11.2021

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 640 Lee Road, Wayne, PA, United States, 19087

Analytics

WallStreet Target Price

3.86 USD

P/E ratio

Dividend Yield

Current Year

+29 752 000 USD

Last Year

+6 761 000 USD

Current Quarter

+9 282 000 USD

Last Quarter

+1 869 000 USD

Current Year

+17 792 000 USD

Last Year

+2 048 000 USD

Current Quarter

+8 434 000 USD

Last Quarter

+277 000 USD

Key Figures ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -84 357 000 USD
Operating Margin TTM -321.88 %
PE Ratio
Return On Assets TTM -29.81 %
PEG Ratio -0.13
Return On Equity TTM -60.94 %
Wall Street Target Price 3.86 USD
Revenue TTM 21 432 000 USD
Book Value 2.21 USD
Revenue Per Share TTM 0.31 USD
Dividend Share
Quarterly Revenue Growth YOY -51.2 %
Dividend Yield
Gross Profit TTM -60 021 000 USD
Earnings Share -1.66 USD
Diluted Eps TTM -1.66 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ACRS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 35.3605
Price Sales TTM 2.9865
Enterprise Value EBITDA 0.3766
Price Book MRQ 0.4094

Financials ACRS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ACRS

For 52 weeks

0.59 USD 18.54 USD
50 Day MA 4.26 USD
Shares Short Prior Month 6 575 688
200 Day MA 7.85 USD
Short Ratio 1.11
Shares Short 7 391 914
Short Percent 12.03 %